Uptrend Under Pressure 93
Institutional selling is building — 7 distribution days in the last 25 sessions. Severe risk · 93/100 · 7 distribution days (SPY) Sep 11 Full briefing →
View
Simple research view

BIO · Bio-Rad Laboratories, Inc.

$368.75 -2.18% Sep 10 close
Detected setup Trend Only · Setup Score 76/100

Stand aside — setup invalidated

Setup score 76, but distribution days reach 5 or more — stand aside until the condition resets.

Ask about BIO

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

$BIO

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. is a large-cap Medical Specialties company in the Health Technology sector with a market cap of $10B.

Health Technology Medical Specialties stock Stage 2 · Advancing Base 2
$368.75 latest close
Join to Watchlist $BIO Share card
Verdict · setup score 76/100 · data Sep 10 close · 1 session old

Stand aside — setup invalidated

Setup score 76, but distribution days reach 5 or more — stand aside until the condition resets.

Review six verdicts Inspect chart
Earnings

Normal technical setup

Next earnings Tuesday, October 27, 2026 After market close Exact clock time not supplied by source

Deterministic evidence

BIO-2.18%
Sector proxy · XLV-0.55%
Broad market · SPY-0.60%
Same completed session window ending 2026-09-10. BIO was -1.63 points vs XLV. -1.58 points vs SPY.

Session internals Weak

Rule: closed flat-to-down and in the bottom third of the range. Judged on internals, not on the size of the move.

Vs prior close-2.18% From the open-1.04% Range position1% GapNo gap
QQQ confirmationConfirming (-1.06%) SMH confirmationConfirming (-2.44%)
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

Ask a Legend to interpret this evidence → Commentary only — never scanner evidence or a sizing recommendation.

Price $368.75 -2.2% Sep 10 close
52W High $396.23 6.9% below high
Wks Since High 2w 1w today
Base Depth 5.5% 7.0% today
RS Rank 70 percentile of scan
SMA 50 $340.93
Avg Vol 274,121
Rel Vol (Sep 10) 1.22×
More stats
52W Low $236.73
Tight Wks 0
Base B2
SMA 200 $303.05
RS Line vs High -4.5%
RS Line Slope +4.8% ▲
Group Rank #25/58
ADR% 2.8%
ATR(14) $10.64 (2.9%)
Vol Pace (live) N/A
U/D Vol 0.75
A/D Days 18A / 14D
A/D Rating A
VDU Bars 0/10 d
Earnings in 45d
Position in 52-week range 83rdpercentile of the 52-week range
$236.73low
$396.23high

BIO Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for BIO.

Create Free Account

Technical Analysis Report Card

$BIO · $368.75 · as of 2026-09-10 · multi-factor read
71
/ 100
Technicals 71/100
Reference read from price & volume only — the verdict at the top of the page decides the action.

Trend · Daily / Weekly / Monthly

Daily ▬ Sideways / consolidating
Weekly ▲ Uptrend
Monthly ▲ Uptrend

Moving Averages

50-day$340.93 ↑
100-day$312.12 ↑
200-day$303.05 ↑
Bullish (50 > 200)

RSI (14)

Reading51.3 · Neutral

Neutral — momentum is balanced between buyers and sellers.

MACD (12/26/9)

StateWeakening
Histogram-3.666

Weakening — MACD slipped below its signal line. Histogram contracting.

Bollinger Bands (20,2)

%B / Width34% · 13.4%

Mid-band — no directional band edge in play.

Volume · Buyer vs Seller

Up/Down vol0.75 · Neutral
Rel volume1.22×

Balanced — up/down volume is roughly even; no clear hand. Recent volume is easing versus its baseline.

Support & Resistance

R · $396.2352-week high
Price · $368.75now
S · $285.39swing level
S · $281.79swing level
S · $270.00swing level

Fibonacci · Uptrend swing

23.6%$358.59
38.2%$335.30
50.0%$316.48
61.8%$297.66
78.6%$270.86

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for BIO — plus the full 500+ symbol scanner and Ask-the-Legends chat.
Start your 7-day free trial →
Weekly uptrendMonthly uptrendAbove 200-day MA50/200 bullish
Want this read in a legend's voice? Ask a Legend about BIO
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 4 of 6 legends are Watching — building, not yet a confirmed buy.
Minervini
Avoid
Minervini C

Trend-template read: fails 150-day MA > 200-day MA.

Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $368.75, MA150 $300.44, MA200 $303.05
1.4 50-day MA > 150-day MA AND 200-day MAMA50 $340.93, MA150 $300.44, MA200 $303.05
Failing evidence
1.2 150-day MA > 200-day MAMA150 $300.44 vs MA200 $303.05
2. ROE ≥ 17%ROE 3.1%
7/11 checks
Method → Playbook → Ask →
O'Neil
Avoid
O'Neil D

CANSLIM read: fails L: RS rank ≥ 80 (IBD leadership).

Passing evidence
C: Quarterly EPS acceleration ≥ 25%+38.6% QoQ
N: Near 52-week high or RS line new high6.9% below high | RS line new high: False
Failing evidence
L: RS rank ≥ 80 (IBD leadership)RS rank 76
A: Annual earnings & revenue qualityRev +0.7% | ROE 3.1%
3/8 checks
Method → Playbook → Ask →
Weinstein
Watch
Weinstein C

Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.

Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $368.75 vs MA200 $303.05
Failing evidence
Volume expansion above averageVolume ratio 1.22x
Weekly price coiling (Stage 2 consolidation)Tightening weekly range confirms base
5/7 checks
Method → Playbook → Ask →
Livermore
Watch
Livermore B

Pivotal-point read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence
Price$368.75
Relative strengthRS 76
Failing evidence
Volume vs average1.22x
Pivotal point cleared on expanding volumeNot confirmed
4/6 checks
Method → Playbook → Ask →
Darvas
Watch
Darvas B

Box-theory read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence
Price$368.75
Relative strengthRS 76
Failing evidence
Volume vs average1.22x
Box top broken on heavy volumeNot confirmed
4/6 checks
Method → Playbook → Ask →
Wyckoff
Watch
Wyckoff B

Supply-and-demand read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence
Price$368.75
Relative strengthRS 76
Failing evidence
Volume vs average1.22x
Sign of Strength confirmed on expanding volumePrice hasn't cleared the pivot yet — confirmation pending
4/6 checks
Method → Playbook → Ask →
Base & Breakout
Breakout follow-through

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

Latest candle: Shooting Star — Long upper shadow with a small body near the low — sellers rejected higher prices. A caution flag when price is extended above a pivot.

Unlock Base & Breakout Tracking
RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▲ Rising
115RS Line (52W)
Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net +5 A
A: 16 D: 11 Net: +565 sessions
Minervini · Grade Card
Fundamentals & leadership quality — Minervini’s published criteria · 4/7 met
B 4/7 criteria
Separate score from the Minervini Trend Template (7/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
✓ EPS acceleration ≥25% QoQ +39%
✗ Revenue growth ≥20% YoY +1%
✓ Gross margin ≥30% 52%
✗ ROE ≥17% 3%
✗ RS rating ≥80 (leadership) 76
✓ Stage 2 uptrend (Weinstein) Stage 2
✓ Within 25% of 52W high -6.9%

Method Playbook

Trade it like Wyckoff EXACT LEVELS · PRO
Wyckoff B · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.
Pivot
Pro level
Published-method rule: Use the Spring/test, Sign of Strength, creek, or Last Point of Support boundary identified by the active structure.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro level
Published-method rule: Require a completed test or Sign of Strength/Last Point of Support confirmation with improving demand versus supply.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro level
Published-method rule: Start below the Spring/test low or structural support whose failure would invalidate the accumulation read.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-based
Published-method rule: Raise protection beneath successive Last Points of Support or meaningful higher lows during markup; never loosen it.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro level
Published-method rule: Exit on a failed Sign of Strength, support loss, or clear supply-dominant reversal such as an upthrust failure.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →

Pattern Analysis

Trend Only
76 setup score
RS Score 76
Trend template 7/8
Why This Setup?
The Universal Edge Check · context only

What the setup still has going for it, recorded for later. The verdict above stands — these principles do not overrule it.

2/7 universals met
  • Risk is defined — not met No stop — undefined risk
  • A relative-strength leader — partly met RS rank 70 — middling
  • Asymmetric reward — partly met No target set
  • Not chasing (in range) — partly met Pivot distance unknown
  • Volume confirms — partly met 1.2× average — light
  • Clear of earnings — met in 45 days
  • In a confirmed uptrend — met Stage 2 · Trend template 7/8
Why these seven? → The Universal Edge

Minervini Trend Template

7/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $368.75 vs SMA150 $300.44 / SMA200 $303.05
SMA 150 above SMA 200 SMA150 $300.44 vs SMA200 $303.05
SMA 200 trending up Slope +6.24 over 20 days
SMA 50 above SMA 150 & 200 SMA50 $340.93
Price above SMA 50 $368.75 vs SMA50 $340.93
30%+ above 52-week low +55.8% from $236.73
Within 25% of 52-week high -6.9% from $396.23
RS score above 70 RS 76

Fundamentals

52W Range
83%
Mkt Cap SEC
10.2B
EPS QoQ
+39%
Rev YoY
+1%
ROE
3%
Gross Margin
52%
D/E
0.16
EPS TTM
$27.85
P/E TTM
13.2x
Float
28M

Company

Company profile
Bio-Rad Laboratories, Inc.
BIO · NYSE · Health Technology · Medical Specialties
Track all markets on TradingView

Weekly Context

Multi-timeframe signals from weekly bars
W. Trend
7/8
W. RS
96
W. Support
$236.73
W. Resist
$396.23
Weekly Structure

Scan History

20× streak
Sep 09: 80 (Trend Only)Sep 10: 81 (Trend Only)Sep 11: 76 (Trend Only)Sep 11: 76 (Trend Only)76
Sep 11
Trend Only ✓ Gate
76
Sep 11
Trend Only ✓ Gate
76
Sep 10
Trend Only ✓ Gate
81 0.0%
Sep 09
Trend Only ✓ Gate
80 -2.2%

Get the full picture on BIO

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 500+ symbols daily.

Start 7-Day Free Trial